It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Restoration of cognitive function in old mice by transfer of blood or plasma from young mice has been attributed to reduced C–C motif chemokine ligand 11 (CCL11) and β2-microglobulin, which are thought to suppress neurogenesis in the aging brain. However, the specific role of the hematopoietic system in this rejuvenation has not been defined and the importance of neurogenesis in old mice is unclear. Here we report that transplantation of young bone marrow to rejuvenate the hematopoietic system preserved cognitive function in old recipient mice, despite irradiation-induced suppression of neurogenesis, and without reducing β2-microglobulin. Instead, young bone marrow transplantation preserved synaptic connections and reduced microglial activation in the hippocampus. Circulating CCL11 levels were lower in young bone marrow recipients, and CCL11 administration in young mice had the opposite effect, reducing synapses and increasing microglial activation. In conclusion, young blood or bone marrow may represent a future therapeutic strategy for neurodegenerative disease.
Melanie Das et al. demonstrate that transplantation of young bone marrow preserves the cognitive function of old recipient mice. This study suggests that microglial rejuvenation via peripheral manipulation of the hematopoietic system may be sufficient to delay a cognitive decline during aging.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Cedars-Sinai Medical Center, Board of Governors Regenerative Medicine Institute, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905); Cedars-Sinai Medical Center, Department of Biomedical Sciences, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
2 Cedars-Sinai Medical Center, Department of Biomedical Sciences, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905); Cedars-Sinai Medical Center, Department of Pediatrics, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
3 Cedars-Sinai Medical Center, Biostatistics and Bioinformatics Research Institute, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)